Wellington Shields Capital Management LLC trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 26.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,810 shares of the medical instruments supplier’s stock after selling 5,800 shares during the quarter. Becton Dickinson and comprises about 0.7% of Wellington Shields Capital Management LLC’s investment portfolio, making the stock its 26th biggest holding. Wellington Shields Capital Management LLC’s holdings in Becton Dickinson and were worth $3,984,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of BDX. Harvest Group Wealth Management LLC bought a new stake in Becton Dickinson and during the 1st quarter valued at about $25,000. TRUE Private Wealth Advisors bought a new stake in Becton Dickinson and during the 2nd quarter valued at about $25,000. Hexavest Inc. bought a new stake in Becton Dickinson and during the 2nd quarter valued at about $28,000. Lipe & Dalton purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at about $28,000. Finally, Pinnacle Financial Partners Inc. purchased a new stake in shares of Becton Dickinson and during the 1st quarter valued at about $29,000. Institutional investors own 82.82% of the company’s stock.
Shares of BDX traded up $2.05 on Thursday, reaching $255.06. The company’s stock had a trading volume of 7,594 shares, compared to its average volume of 1,152,793. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. The stock has a market capitalization of $68.93 billion, a P/E ratio of 23.16, a PEG ratio of 1.81 and a beta of 1.11. The stock’s 50 day simple moving average is $251.26 and its two-hundred day simple moving average is $244.60. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. The company had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm’s revenue was up 1.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.91 earnings per share. Analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total transaction of $687,836.82. Following the transaction, the executive vice president now owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The disclosure for this sale can be found here. In the last three months, insiders sold 8,444 shares of company stock worth $2,061,288. 0.12% of the stock is currently owned by insiders.
BDX has been the topic of a number of recent analyst reports. UBS Group dropped their price target on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Piper Jaffray Companies dropped their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Co dropped their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, Raymond James raised their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $264.27.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.